8-K: Shattuck Labs Announces Positive Clinical Data and Secures Funding, Extending Cash Runway into 2026

Shattuck Labs reported positive clinical trial data for its lead drug candidate, SL-172154, and secured $50 million in funding, extending its cash runway into 2026.

Summary

• Shattuck Labs announced its financial results for the fourth quarter and full year of 2023, along with key business updates.
• The company's lead drug candidate, SL-172154, showed promising results in Phase 1B trials for HR-MDS, TP53m AML, and PROC, with data suggesting improved response rates compared to standard treatments.
• Shattuck completed a $50 million offering of common stock and pre-funded warrants in Q4 2023, extending its cash runway into 2026.
• A strategic collaboration with Ono Pharmaceutical was established, potentially bringing in up to $227 million in milestone payments and royalties.
• The company's cash and cash equivalents and investments totaled $130.6 million as of December 31, 2023, down from $161.3 million the previous year.
• Research and development expenses decreased to $74.3 million for the year ended December 31, 2023, compared to $82.9 million in 2022.
• Net loss for the year was $87.3 million, an improvement from the $101.9 million loss in 2022.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical data, a significant collaboration, and extended cash runway. While there are inherent risks in drug development, the overall tone is optimistic and suggests a strong trajectory for the company.

Positives

• Positive interim data from Phase 1B trials of SL-172154 in multiple cancer indications suggest improved efficacy over standard treatments.
• The strategic collaboration with Ono Pharmaceutical provides significant potential revenue through milestone payments and royalties.
• The $50 million capital raise strengthens the company's financial position and extends its operational runway.
• The company's cash runway is now projected to extend into 2026.
• Net losses have decreased year-over-year, indicating improved financial management.
• The company has made progress in its preclinical pipeline, as evidenced by publications in Cancer Cell and Cancer Research.

Negatives

• Cash and cash equivalents decreased from $161.3 million in 2022 to $130.6 million in 2023.
• The company reported a net loss of $87.3 million for the year ended December 31, 2023, although this is an improvement from the $101.9 million loss in 2022.
• Research and development expenses, while decreased year-over-year, still represent a significant cost for the company.

Risks

• Clinical trial results may not continue to be positive, and the drug may not receive regulatory approval.
• The company's financial projections are based on current operational plans and exclude potential additional costs or revenue.
• The collaboration with Ono Pharmaceutical is subject to the successful achievement of milestones.
• The company is subject to various risks and uncertainties, including those related to global macroeconomic conditions and regulatory approvals.

Future Outlook

Shattuck believes its current cash and investments will be sufficient to fund operations into 2026, beyond the results from its Phase 1 clinical trials of SL-172154. The company anticipates sharing updated clinical data mid-year 2024 and defining its registrational strategy.

Management Comments

• Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck, stated that the SL-172154 program rapidly transitioned from Phase 1A dose-escalation studies to Phase 1B dose expansion studies in PROC, HR-MDS, and TP53m AML.
• He also mentioned that the company has begun 2024 with the momentum and financial resources to expand its HR-MDS and TP53m AML studies and capitalize on the potential first-in-class opportunity in those indications.
• Management looks forward to providing additional updates across the portfolio over the course of 2024.

Industry Context

This announcement is significant in the context of the competitive landscape of cancer and autoimmune disease therapeutics. Shattuck's focus on bi-functional fusion proteins represents a novel approach, and the positive clinical data could position them as a key player in the field. The collaboration with Ono also highlights the growing interest in innovative therapies for these diseases.

Comparison to Industry Standards

• The reported response rates for SL-172154 in combination with AZA in HR-MDS and TP53m AML appear to be better than historical results with AZA alone, which is a common treatment for these conditions. Companies such as Celgene (now part of Bristol Myers Squibb) with drugs like Revlimid and Vidaza are benchmarks in this space.
• In PROC, the improved response rate of SL-172154 with PLD compared to PLD alone is encouraging. Standard treatments for PROC include chemotherapy agents like PLD and targeted therapies such as bevacizumab. Companies like Immunogen with their antibody-drug conjugate mirvetuximab soravtansine are also key competitors in this space.
• The collaboration with Ono is similar to other strategic partnerships in the biotech industry, where companies combine their expertise and resources to develop new therapies. For example, many companies partner with larger pharmaceutical companies to accelerate development and commercialization.

Stakeholder Impact

• Shareholders may view the positive clinical data and extended cash runway favorably.
• Employees may be encouraged by the company's progress and financial stability.
• Patients with cancer and autoimmune diseases may benefit from the development of new therapies.
• The collaboration with Ono could lead to new opportunities for suppliers and partners.

Next Steps

• Shattuck plans to continue enrollment in Phase 1B dose-expansion cohorts for frontline HR-MDS and TP53m AML patients.
• The company expects to share updated combination data from these trials mid-year 2024.
• Shattuck will continue dosing in the Phase 1B clinical trial of SL-172154 in combination with mirvetuximab soravtansine in PROC patients.
• The company plans to attend several investor and scientific conferences in the coming months.
• Shattuck will lead research and preclinical development of certain compounds selected by Ono from its pipeline of bifunctional fusion proteins.

Key Dates

Keywords

SL-172154, bifunctional fusion proteins, cancer, autoimmune disease, clinical trials, HR-MDS, AML, PROC, Ono Pharmaceutical, capital raise, biotechnology